TCL Archive Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer July 26, 2002
TCL Archive CCIRC Disapproves NCOG Renewal, But Carter Plan Appeal To NCAB; Setback For NCI On Regional Groups March 6, 1981